EQ Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 44
- Market Cap
- $36.8M
- Website
- http://www.equilliumbio.com
- Introduction
EQ Inc is a provider of digital marketing services. It operates in a single segment, which is to provide real-time technology and advanced analytics to improve performance for web, mobile, social, and video advertising initiatives and focuses on targeted advertising and incorporates advertising technologies, data analytics, and programmatic media buying capa...
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Equillium
- Target Recruit Count
- 36
- Registration Number
- NCT05589610
- Locations
- 🇦🇺
Premier Specialists, Kogarah, Australia
🇦🇺Sinclair Dermatology, East Melbourne, Australia
🇦🇺Fremantle Dermatology, Fremantle, Australia
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Equillium
- Target Recruit Count
- 200
- Registration Number
- NCT05263999
- Locations
- 🇦🇺
Royal Melbourne Hospital, East Melbourne, Australia
🇦🇺Austin Health, Heidelberg, Australia
🇦🇺Westmead Hospital, Westmead, Australia
A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Equillium
- Registration Number
- NCT04605926
- Locations
- 🇨🇴
Inv Site CO01, Medellín, Colombia
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Equillium
- Target Recruit Count
- 55
- Registration Number
- NCT04128579
- Locations
- 🇺🇸
Northwell Health / Division of Rheumatology, Great Neck, New York, United States
🇺🇸Omega Research Maitland, LLC, Orlando, Florida, United States
🇺🇸AKDHC Medical Research Services, LLC, Sun City, Arizona, United States
A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Equillium
- Target Recruit Count
- 18
- Registration Number
- NCT04007198
- Locations
- 🇦🇺
Monash Medical Centre, Clayton, Australia
🇦🇺Flinders Medical Centre, Adelaide, Australia
🇦🇺Box Hill Hospital, Box Hill, Australia
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Equillium
- Target Recruit Count
- 30
- Registration Number
- NCT03763318
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸University of Florida Health Shands Hospital, Gainesville, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Equillium
- Registration Number
- NCT03532958